CEO Christopher Viehbacher has said consistently since he took the helm of Biogen in 2022 that the company will grow through both internal and external innovation, with an overarching goal of diversifying beyond neurology further into rare diseases and immunology. The hiring of Jane Grogan as head of research a year later reinforced that strategy and the new member of the leadership team told Scrip that she spent 2024 reorganizing her group with those overarching goals in mind.
Key Takeaways
- Biogen head of research Jane Grogan spoke to Scrip about reorienting the company’s research group to focus on the highest...
Grogan is an immunologist by training. She led immunology and immuno-oncology R&D programs at Genentech and more recently served as chief scientific officer of the cell...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
